Study for children with relapsed high-risk ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 18 at the time they join the study
- The leukemia is ALL that has come back (first relapse), confirmed by lab testing
- The relapse type matches the study’s “high-risk” groups (certain bone marrow or early/combined extra sites)
- The child is treated at a participating hospital and starts treatment during the study time window
- You and your child (if applicable) can give consent and agree to share de-identified medical data for research
- Your child has not been in another conflicting clinical trial in the 30 days before enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This trial tests a chemotherapy combination that includes bortezomib for people whose acute lymphoblastic leukemia (ALL) has come back or not responded to previous treatments. It aims to offer a new option for those who haven't tried bortezomib before.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests new combinations of targeted drugs (inotuzumab ozogamicin and blinatumomab) for children whose B-cell acute lymphoblastic leukemia (ALL) has come back for the first time. It aims to find the best treatment based on how well the leukemia responds.
Hear when a new Acute Lymphoblastic Leukemia (ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.